A look at the shareholders of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) can tell us which group is most…

from Yahoo Finance https://ift.tt/3hX0AL8

Tao Value recently released its Q2 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 36.45% for the quarter, outperforming its benchmark, the MSCI All Country World Index (ACWI) which returned 18.81% in the same quarter. You should check out Tao Value's top 5 stock picks for […]

from Yahoo Finance https://ift.tt/30aYn95

After a market crushing performance during the first half of the year, one of 2020’s best performers has been struggling of late. The last month has seen shares of Inovio Pharmaceuticals (INO) decline by 27%. The publication of murky data for the biotech’s COVID-19 DNA vaccine candidate INO-4800 and a sense it is lagging behind competitors’ progress have raised concerns amongst investors. Add in an overheated valuation and maybe a sell off was inevitable.As a reminder, despite the souring sentiment, the stock is still up by a majestic 510% on a year-to-date basis.With the public and investors’ focus squarely on COVID-19 related developments, it is easy to forget these companies have other drugs in various states of development.On Thursday, Inovio shares broke out of the downtrend and surged by 9%. For a change the uptick had nothing to do with COVID-19.Which brings us to INO-3107, Inovio’s treatment for recurrent respiratory papillomatosis (RRP). Inovio announced INO-3107 had been designated Orphan Drug status by the FDA. The status is given to rare diseases with a small addressable market that otherwise not be profitable enough to develop, therefore the government steps in to provide support. The designation should provide Inovio with various incentives, including seven years of market exclusivity should the treatment gain FDA approval, a prescription drug user fee waiver, and tax credits for qualified clinical trials.INO-3107 is currently being evaluated in a Phase 1/2 trial with 63 subjects participating in the study. Defined by the growth of noncancerous tumors that can result in life-threatening airway obstructions, there are currently 15,000 RRP cases in the U.S.H.C.Wainwright analyst Ram Selvaraju commented, "These incentives could help the company advance future clinical development of INO-3107 and maximize the DNA medicine’s commercial value, in our view… We believe INO-3107 has the potential to address the underlying recurring virus, delay or eliminate the need for frequent surgery, and provide a long term treatment option to improve the quality of life for both adult and pediatric RRP patients.”However, it is still early days in the drug’s development and for now Selvaraju stays on the sidelines with a Neutral rating. (To watch Selvaraju’s track record, click here)Selvaraju’s colleagues agree. Inovio currently has a Hold consensus rating, based on 2 Buys, 5 holds and 1 Sell. The average price target comes in at $22 and implies shares will remain range bound for now. (See Inovio stock-price forecast on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

from Yahoo Finance https://ift.tt/3jXnwvD

ConocoPhillips (NYSE:COP) has had a rough month with its share price down 7.6%. However, stock prices are usually…

from Yahoo Finance https://ift.tt/2XeKghf

Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500's (NYSE: SPY) total return for the decade was 250.5%. But there's no question some big-name stocks did much better than others along the way.Kodak's Difficult Decade: One underperformer of the last decade was former camera giant Eastman Kodak Company (NYSE: KODK).Kodak's decade was defined by a bankruptcy and two major strategic pivots away from its legacy camera business.Extreme cash burn and a secular decline in Kodak's camera and inkjet printing businesses triggered a Chapter 11 bankruptcy in January 2012. The bankruptcy completely wiped out legacy shareholders, and Kodak's peak market cap of around $30 billion went down to $0.Kodak re-emerged from bankruptcy and relisted shares in November 2013 starting at $26.50 per share. Kodak's updated business model included segments Digital Printing & Enterprise and Graphics, Entertainment & Commercial Films.When the restructured company continued to struggle to gain traction, Kodak made a seemingly desperate move by pivoting to blockchain technology in January 2018 near the peak of the bitcoin bubble. After reporting declining revenues and a $111 million net loss in the first quarter of 2020, Kodak once again pivoted to producing generic drug ingredients in July, announcing a brand new $765 million loan from the U.S. government.After opening at $26.50 post-bankruptcy in late 2013, Kodak shares peaked at $37.73 in early 2014 before resuming the steady march downward that long-time investors had endured since the 1990s.Kodak shares dropped as low as $2.95 in late 2017 before the blockchain pivot sent the stock skyrocketing as high as $13.27 in January, 2018. By late 2018, Kodak was making new lows again.2020 And Beyond: After hitting an all-time low of $1.50 in March 2020, Kodak shares skyrocketed to new all-time highs on the drug news just four months later. Kodak shares peaked at $60 in the days following the announcement before pulling back to around $36.Even after the massive 2020 run, Kodak shares have significantly lagged the S&P 500 since it emerged from bankruptcy in 2013. In fact, $1,000 worth of Kodak stock in 2013 would be worth about $1,384 today.At the same time, $1,000 worth of legacy Kodak stock purchased in 2010 would now be worth $0 due to the bankruptcy.Related Links:Here's How Much Investing ,000 In Nokia Stock Back In 2010 Would Be Worth Today Here's How Much Investing ,000 In Pfizer Stock Back In 2010 Would Be Worth TodaySee more from Benzinga * Kodak Short Sellers Are Getting Obliterated * A Closer Look At The Kodak Chairman's Stock Purchases As Shares Rally 1,500% * Kodak Had Some Very Suspicious Trading Activity Ahead Of Drug News(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

from Yahoo Finance https://ift.tt/2XfA7R9

from Yahoo Finance https://ift.tt/3jRSXHM

(Bloomberg) — Under Armour Inc. managed to reach more customers than expected last quarter, even with most of its stores closed — but the road ahead is looking bumpy.The athletic-goods maker’s second-half revenue is likely to fall 20% to 25%, with its recently improved gross margin coming under new pressure, executives warned on a call with analysts Friday. The volatile stock soared in premarket trading after second-quarter revenue beat estimates, but it gave up the gains after the open, falling as much as 7.3% to $10.61 in New York.The company expects pressure on its gross margin in the second half of the year, and might not have enough inventory if sales recover faster than expected, executives said on the call.That would be a comedown from a second quarter in which Under Armour’s gross margin rose to 49.3% from 46.5% a year earlier. The company cited fewer off-price sales and more direct-to-consumer transactions as homebound shoppers ordered online.Second-quarter revenue fell 41% from a year earlier to $707.6 million, but that handily topped the highest estimate of $596 million, according to a Bloomberg survey of analysts.The company responded to the Covid-19 slowdown by “amplifying Under Armour’s connection with our consumers through innovative digital activations” and “proactively managing our cost structure,” Chief Executive Officer Patrik Frisk said in a statement.The Baltimore-based company didn’t address the notices that founder Kevin Plank and Chief Financial Officer David Bergman received from the U.S. Securities and Exchange Commission last week, naming the two in a probe of the company’s accounting.For more details on the earnings, click here for our TOPLive blog.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/3fgkBe0

Every investor in United States Steel Corporation (NYSE:X) should be aware of the most powerful shareholder groups…

from Yahoo Finance https://ift.tt/3hYyxeB

Tao Value recently released its Q2 2020 Investor Letter, a copy of which you can download here. The fund posted a return of 36.45% for the quarter, outperforming its benchmark, the MSCI All Country World Index (ACWI) which returned 18.81% in the same quarter. You should check out Tao Value's top 5 stock picks for […]

from Yahoo Finance https://ift.tt/2X9TXxe

Starbucks Corporation (NASDAQ:SBUX) just released its third-quarter report and things are looking bullish. It looks…

from Yahoo Finance https://ift.tt/30eM5g0